跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 58 条关于
“ArriVent”
全部
58
临床试验
38
药物
1
机构
2
资讯
17
去年
ArriVent Biopharma Secures Strong Financial Position with $266.5M Cash Reserve Following Successful IPO
去年
ArriVent BioPharma Raises $75 Million to Advance Firmonertinib and Cancer Pipeline
去年
ArriVent BioPharma Expands Portfolio with Novel ADC for GI Cancers, Reports Strong NSCLC Trial Results
12个月前
ArriVent BioPharma Appoints Brent Rice as Chief Commercial Officer to Lead Firmonertinib Commercialization
上个月
ArriVent Advances Firmonertinib Toward Pivotal EGFR Exon 20 NSCLC Data as ADC Pipeline Progresses
9个月前
ArriVent Initiates Pivotal Phase 3 ALPACCA Trial for Firmonertinib in EGFR PACC Mutant NSCLC
2年前
Metagenomi Aims for $87M IPO to Advance Novel Gene Editing Platform
9个月前
Alphamab Oncology Receives IND Approval for First-in-Class PD-L1/VEGFR2 Bispecific ADC JSKN027
11个月前
Roche Acquires Hansoh's CDH17-Targeting ADC HS-20110 in $1.45 Billion Deal
去年
Alphamab Oncology Receives IND Approval for First-in-Class Bispecific ADC JSKN022 Targeting PD-L1 and Integrin αvβ6
第 1 页,共 2 页
上一页
下一页